JNJ: Company disclosure

Item 7.01 Regulation FD Disclosure On July 27, 2026, the Company announced that it has reached an agreement for a comprehensive resolution of the ovarian talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned upon, among other things, the express participation of at least of 95% of the remaining claims. The agreement calls for per claim payments, with a $5.5 billion commitment by the Company, and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028. The press release further discussing this announcement is attached below as Exhibit 99.1. Item 9.01 Financial statements and exhibits (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated July 27 , 2026 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 27, 2026 JOHNSON & JOHNSON (Registrant) By: /s/ Marc Larkins Marc Larkins Corporate Secretary